Pyx Health Acquires FarmboxRx With $47.5M Funding Boost
Acquiring FarmboxRx will help Pyx Health tackle food insecurity, a challenge many of its members struggle with.
J&J Bolsters Its Prospects in Brain Health With $14B Buyout of Intra-Cellular Therapies
Johnson & Johnson’s agreement to acquire Intra-Cellular Therapies brings Caplyta, which is projected to become a blockbuster seller across several neurological indications. In other M&A news, GSK and Eli Lilly each struck deals to fill their cancer drug pipelines.
presented by
Everything You Need to Know About Who Accredits Health Plans for Mental Health Parity Compliance
Who accredits health plans for mental health parity compliance? Learn about the only organization that offers this program to ensure your members get equitable care.
Private Equity Buys Another Piece of Baxter as Carlyle Scoops Up Kidney Care Biz for $3.8B
Baxter International is selling its kidney care business for less than it was able to fetch for its much smaller biopharma solutions segment last year. A unit within kidney care took a goodwill impairment charge, Baxter’s financial reports show.
Will A Divestiture Save the UnitedHealth Group-Amedisys Deal?
Amedisys and UnitedHealth Group plan to divest care centers to an affiliate of VitalCaring Group. Several experts said this will likely clear the way for the companies' merger.
AbbVie Expands IBD Drug Pipeline Again With $250M Celsius Therapeutics Acquisition
AbbVie has acquired Celsius Therapeutics, a startup whose lead program is in early clinical development for inflammatory bowel disease. It’s the latest in a series of AbbVie business deals that broaden the pharma company’s scope in the gastrointestinal condition.
NeuroFlow Acquires 2nd Behavioral Health Company in 1 Year
NeuroFlow acquired Owl, a provider of measurement-based behavioral health care. These types of consolidations will drive the future of behavioral health care, according to NeuroFlow CEO Chris Molaro.
presented by
5 Companies That Offer Mobile IV Therapy With Experienced Nurses in NYC and Beyond
Get your IV treatment from wherever you are. These top companies provide mobile IV therapy administered by experienced nurses in NYC and beyond.
Merck Sees Pipeline Diversification Opportunity in $1.3B EyeBio Acquisition
Merck’s EyeBio acquisition brings a lead program ready for pivotal testing in diabetic macular edema. The therapy could pose competition to Eylea, the blockbuster Regeneron Pharmaceuticals eye drug.
Hospital M&A Activity in 2024: What to Expect
Q1 2024 saw a significant rise in the number of hospital M&A deals compared to the past three Q1s. Experts believe this M&A activity will continue to climb throughout this year and next — motivated by both financial distress and hospitals’ desire to improve strategic business lines like value-based care and digital healthcare services.
Labcorp’s $237M Tuck-In Deal Brings Lab Testing Assets From BioReference Health
Labcorp is buying the clinical diagnostics and reproductive women’s health businesses of BioReference Health, excluding those assets in New York and New Jersey. Labcorp has returned to being fully focused on lab testing after last year’s spinoff of Fortrea, its former clinical trial services business.
Novo Nordisk Expands Cardio Reach by Buying Heart Drugs Biotech Cardior
Novo Nordisk’s strategy to grow beyond metabolic diseases includes expanding into adjacent areas such as cardiovascular disease. Acquiring Cardior Pharmaceuticals adds a novel RNA-based therapy that is a potential heart failure treatment.
presented by
The 6 Most Affordable Workflow Optimization Tools for Radiology
Radiologists today face a surge in imaging volume and pressure to produce fast, accurate reports. Workflow optimization is about delivering the right results at the right time with less friction.
Bristol Myers Squibb Makes Another M&A Move, Striking $4B Deal for RayzeBio
By acquiring RayzeBio, Bristol Myers Squibb gains a pipeline of radiopharmaceuticals and the infrastructure for manufacturing these targeted cancer therapies. In the second half of 2023 alone, BMS has committed about $24 billion to business development deals.
Covera Health Acquires CoRead, Secures up to $50M To Improve Radiology
Covera Health has finalized its acquisition of CoRead, the companies announced last week but did not disclose the terms of the deal. Covera also announced that it raised up to $50 million in additional Series C funding led by Insight Partners.
A One-Time Treatment for NASH? Kriya Strikes Deal for Liver Disease Gene Therapy
Gene therapy biotech Kriya Therapeutics has acquired Tramontane Therapeutics, a startup focused on metabolic diseases. Tramontane brings a gene therapy that’s a potential one-time treatment for the fatty liver disease NASH.
Danaher Continues M&A Streak, Buying Life Sciences Firm Abcam for $5.7B
Abcam’s acquisition comes two months after its board announced the exploration of strategic alternatives that could include the sale of the company. Danaher beat out at least 20 companies that were potential buyers of the life sciences tools and antibody development firm.
Bausch + Lomb Broadens Eye Products Lineup Via $1.75B Deal With Novartis
Dry eye disease drug Xiidra is the centerpiece of the Bausch + Lomb acquisition. The deal with Novartis also includes two experimental products, one for eye pain and the other a medical device for delivering medicines to the eye.